Jazz Pharmaceuticals plc (JAZZ) Stock Score, Valuation & Financial Research
Jazz Pharmaceuticals plc is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 27/100.
Quick answer for JAZZ
Jazz Pharmaceuticals plc currently has a Wall Street Score of 27/100. The stored market price is $245.8. Its financial score is 20/100. Its valuation score is 0/100. These figures are a research snapshot, not a buy or sell recommendation.
What Jazz Pharmaceuticals plc does
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Modeyso for the treatment of diffuse midline glioma harboring an H3 K27M mutation; and Defitelio to treat severe veno-occlusive disease. It also develops Za
JAZZ financial snapshot
- Wall Street Score:
- 27/100
- Current price:
- $245.8
- Market capitalization:
- $15.44B
- Revenue:
- $4.44B
- Net income:
- $29.5M
- Free cash flow:
- $1.15B
- Cash:
- $1.84B
- Total debt:
- $5.42B
- EPS:
- -5.84
- Financial score:
- 20/100
- Valuation score:
- 0/100
- Revenue score:
- 12/100
What stands out
- Reported year-over-year revenue growth is +0.0%.
- Free cash flow is $1.15B, showing positive cash generation.
- The balance sheet shows $1.84B of cash versus $5.42B of total debt, so leverage deserves attention.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 20/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-07-24.
How to research JAZZ
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.